EVs encapsulating miR-1246 could increase the survival of leukemic stem cells (LSCs) in AML patients through targeting LRIG1 and STAT-3 signaling pathway and thereby induce poor outcomes in the patients. This evidence concerns the gene LRIG1 and acute myeloid leukemia.